Your browser doesn't support javascript.
loading
Impaired Gastrointestinal Motility and Worsening Heart Failure in Patients Receiving Trans-Catheter Aortic Valve Replacement.
Imamura, Teruhiko; Narang, Nikhil; Ushijima, Ryuichi; Sobajima, Mitsuo; Fukuda, Nobuyuki; Ueno, Hiroshi; Kinugawa, Koichiro.
Afiliação
  • Imamura T; The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
  • Narang N; Advocate Christ Medical Center, Oak Lawn, IL 60453, USA.
  • Ushijima R; The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
  • Sobajima M; The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
  • Fukuda N; The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
  • Ueno H; The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
  • Kinugawa K; The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan.
J Clin Med ; 13(15)2024 Jul 23.
Article em En | MEDLINE | ID: mdl-39124567
ABSTRACT

Background:

Impaired gastric motility in the form of constipation may often occur in elderly patients with chronic heart failure. Candidates for trans-catheter aortic replacement (TAVR) are of old age and have multiple comorbidities, probably including constipation. However, the clinical implication of a history of constipation in patients receiving TAVR remains unknown.

Methods:

Patients who underwent TAVR at our large academic center between 2015 and 2022 were eligible. The prognostic impact of the prescribed laxative type and number, which was assumed as the severity of constipation, on the incidence of death or heart failure readmission two years after index discharge was investigated.

Results:

A total of 344 patients were included. Median age was 85 years, and 99 patients were men. Patients with any laxatives (N = 166) had higher systolic blood pressure, higher plasma B-type natriuretic peptide levels, and a lower prescription rate of renin-angiotensin system inhibitors at the time of index discharge after TAVR (p < 0.05 for all). The number of laxative types was independently associated with the composite primary outcome with an adjusted hazard ratio of 1.83 (95% confidence interval 1.27-2.63, p = 0.001) with a cutoff of one type of laxative used, which significantly stratified the 2-year cumulative incidence of the primary outcome (18% versus 7%, p = 0.001).

Conclusions:

The presence of constipation was associated with worse clinical outcomes following TAVR. The prognostic impact of an aggressive intervention for constipation remains a future concern in this cohort.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article